Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWIFT: Semaglutide, Weight Loss, and LNG-IUD for Endometrial Hyperplasia and Cancer
NCT07820358Phase 2Not yet recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Jan 2027
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in endometrial atypical hyperplasia (AEH), endometrial cancer (EC), sponsored by Houston Methodist Research Institute. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
03
Conditions
endometrial atypical hyperplasia (AEH)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07820358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07820358.